Krka Group
https://www.krka.biz/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Krka Group
Chikungunya Vaccine, Hemophilia B Gene Therapy Among 14 Products On Track For EU Approval
The EU is on track to get its first vaccine for preventing the disease caused by chikungunya virus. Thirteen other products have also been recommended for pan-EU approval.
Sandoz And Bio-Thera Get EU Nod For Bevacizumab
At its May meeting, the EMA’s CHMP has issued positive opinions for Sandoz and Bio-Thera’s Avzivi partnered biosimilar rival to Avastin, as well as five generics that included a trio of pomalidomide products.
Krka Out Of The Blocks Solidly In Q1, With Russia Still Largest Market
Krka has reaffirmed its full-year financial goals after a solid start to 2024, which included 8% revenue growth for its pharmaceutical products. Generics Bulletin examines the company’s sprawling global operations.
Krka To Plant Its Flag In India With Laurus Labs JV
Delivering record annual sales and profits according to preliminary financial results, Slovenia’s Krka will soon look to set up shop in India via a new company established with local big player Laurus Labs.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Krka DD, Krka d.d., Krka Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice